RenovoRx Expands RenovoCath Use to Sarcoma, Broadening Solid Tumor Applications
Event summary
- RenovoRx's RenovoCath device was used commercially for the first time to treat a sarcoma patient at CARTI Cancer Center in late June 2026.
- The treatment marks an expansion of RenovoCath's use beyond pancreatic cancer to other solid tumors.
- CARTI is concurrently using RenovoCath for localized drug delivery in pancreatic cancer treatment.
- RenovoRx reported $1.1 million in RenovoCath sales for 2025 and $563,000 in Q1 2026.
The big picture
RenovoRx's expansion into sarcoma treatment with RenovoCath highlights the growing trend of localized drug delivery in oncology, potentially reducing systemic toxicity. The company's strategic shift to broader solid tumor applications could position it as a key player in targeted cancer therapies, provided clinical outcomes and regulatory approvals align with expectations.
What we're watching
- Market Expansion
- How quickly RenovoRx can secure additional medical institutions to adopt RenovoCath for diverse solid tumors.
- Clinical Outcomes
- Whether early results from sarcoma treatment will validate RenovoCath's efficacy in other tumor types.
- Regulatory Pathway
- The pace at which RenovoRx can expand FDA-cleared indications for RenovoCath beyond its current scope.
Related topics